Endothelin A receptor antagonists in diabetic kidney disease

Panagiotis I. Georgianos, Rajiv Agarwal

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of review Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high. The purpose of this review is to discuss the potential role of endothelin antagonism as a therapeutic tool to reduce residual proteinuria and delay kidney injury progression among patients with diabetic nephropathy. Recent findings Preclinical studies have shown that endothelin receptor antagonists (ERAs) exert proteinuria lowering and nephroprotective actions in experimental models of diabetic nephropathy. ERAs reduce proteinuria in phase 2 trials that included therapy with renin-angiotensin-aldosterone system blockers. Safety of these agents and protection from ESRD needs to be demonstrated in phase 3 trials. Excess risk of fluid retention and heart failure risk remains. Summary The hypothesis that the antiproteinuric effect of endothelin antagonism may be translated into a slower progression of diabetic nephropathy to ESRD is investigated in ongoing randomized trials assessing 'hard' renal endpoints. ERAs may represent a promising tool toward renoprotection in diabetic nephropathy by individualizing therapy and mitigating the risk of heart failure, if these trials are positive.

Original languageEnglish (US)
Pages (from-to)338-344
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume26
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Diabetic Nephropathies
Proteinuria
Chronic Kidney Failure
Endothelins
Renin-Angiotensin System
Heart Failure
Kidney
Therapeutics
Theoretical Models
Endothelin A Receptor Antagonists
Safety
Wounds and Injuries
Endothelin Receptor Antagonists

Keywords

  • diabetic nephropathy
  • endothelin antagonism
  • kidney injury progression
  • proteinuria

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Cite this

Endothelin A receptor antagonists in diabetic kidney disease. / Georgianos, Panagiotis I.; Agarwal, Rajiv.

In: Current Opinion in Nephrology and Hypertension, Vol. 26, No. 5, 01.09.2017, p. 338-344.

Research output: Contribution to journalReview article

@article{4dea5df95fbe43e284f450d47bc2f541,
title = "Endothelin A receptor antagonists in diabetic kidney disease",
abstract = "Purpose of review Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high. The purpose of this review is to discuss the potential role of endothelin antagonism as a therapeutic tool to reduce residual proteinuria and delay kidney injury progression among patients with diabetic nephropathy. Recent findings Preclinical studies have shown that endothelin receptor antagonists (ERAs) exert proteinuria lowering and nephroprotective actions in experimental models of diabetic nephropathy. ERAs reduce proteinuria in phase 2 trials that included therapy with renin-angiotensin-aldosterone system blockers. Safety of these agents and protection from ESRD needs to be demonstrated in phase 3 trials. Excess risk of fluid retention and heart failure risk remains. Summary The hypothesis that the antiproteinuric effect of endothelin antagonism may be translated into a slower progression of diabetic nephropathy to ESRD is investigated in ongoing randomized trials assessing 'hard' renal endpoints. ERAs may represent a promising tool toward renoprotection in diabetic nephropathy by individualizing therapy and mitigating the risk of heart failure, if these trials are positive.",
keywords = "diabetic nephropathy, endothelin antagonism, kidney injury progression, proteinuria",
author = "Georgianos, {Panagiotis I.} and Rajiv Agarwal",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MNH.0000000000000342",
language = "English (US)",
volume = "26",
pages = "338--344",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Endothelin A receptor antagonists in diabetic kidney disease

AU - Georgianos, Panagiotis I.

AU - Agarwal, Rajiv

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of review Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high. The purpose of this review is to discuss the potential role of endothelin antagonism as a therapeutic tool to reduce residual proteinuria and delay kidney injury progression among patients with diabetic nephropathy. Recent findings Preclinical studies have shown that endothelin receptor antagonists (ERAs) exert proteinuria lowering and nephroprotective actions in experimental models of diabetic nephropathy. ERAs reduce proteinuria in phase 2 trials that included therapy with renin-angiotensin-aldosterone system blockers. Safety of these agents and protection from ESRD needs to be demonstrated in phase 3 trials. Excess risk of fluid retention and heart failure risk remains. Summary The hypothesis that the antiproteinuric effect of endothelin antagonism may be translated into a slower progression of diabetic nephropathy to ESRD is investigated in ongoing randomized trials assessing 'hard' renal endpoints. ERAs may represent a promising tool toward renoprotection in diabetic nephropathy by individualizing therapy and mitigating the risk of heart failure, if these trials are positive.

AB - Purpose of review Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high. The purpose of this review is to discuss the potential role of endothelin antagonism as a therapeutic tool to reduce residual proteinuria and delay kidney injury progression among patients with diabetic nephropathy. Recent findings Preclinical studies have shown that endothelin receptor antagonists (ERAs) exert proteinuria lowering and nephroprotective actions in experimental models of diabetic nephropathy. ERAs reduce proteinuria in phase 2 trials that included therapy with renin-angiotensin-aldosterone system blockers. Safety of these agents and protection from ESRD needs to be demonstrated in phase 3 trials. Excess risk of fluid retention and heart failure risk remains. Summary The hypothesis that the antiproteinuric effect of endothelin antagonism may be translated into a slower progression of diabetic nephropathy to ESRD is investigated in ongoing randomized trials assessing 'hard' renal endpoints. ERAs may represent a promising tool toward renoprotection in diabetic nephropathy by individualizing therapy and mitigating the risk of heart failure, if these trials are positive.

KW - diabetic nephropathy

KW - endothelin antagonism

KW - kidney injury progression

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=85019644000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019644000&partnerID=8YFLogxK

U2 - 10.1097/MNH.0000000000000342

DO - 10.1097/MNH.0000000000000342

M3 - Review article

VL - 26

SP - 338

EP - 344

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 5

ER -